Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Monopar Therapeutics in a research note issued on Tuesday, August 26th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.51) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.35) EPS.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.
MNPR has been the subject of several other research reports. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $74.00 target price on shares of Monopar Therapeutics in a research note on Wednesday. Finally, Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $66.00.
View Our Latest Stock Report on Monopar Therapeutics
Monopar Therapeutics Price Performance
Shares of Monopar Therapeutics stock opened at $34.81 on Thursday. The firm has a market cap of $214.78 million, a PE ratio of -10.45 and a beta of 1.05. Monopar Therapeutics has a 1 year low of $2.25 and a 1 year high of $54.30. The stock has a fifty day moving average price of $37.81 and a 200-day moving average price of $37.15.
Insiders Place Their Bets
In other news, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares in the company, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock worth $1,700,160 over the last quarter. 20.50% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Monopar Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $45,000. Geode Capital Management LLC lifted its holdings in Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after purchasing an additional 24,530 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Monopar Therapeutics during the 4th quarter worth about $11,247,000. Janus Henderson Group PLC bought a new position in Monopar Therapeutics in the 4th quarter worth about $23,435,000. Finally, Point72 Asset Management L.P. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Institutional investors own 1.83% of the company's stock.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
